Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)~* Have a BMI ≥27 kg/m² and \<30 kg/m² with at least 1 of the following weight-related comorbidities eg; \[Have hypertension, or dyslipidemia, cardiovascular disease\]~* Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)~Exclusion Criteria:~* Have any prior diagnosis of diabetes~* Have a prior or planned surgical treatment for obesity~* Have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity~* Have renal impairment measured as estimated glomerular filtration rate (eGFR) \<30 milliliter (mL)/minute (min)/1.73 m²~* Have a history of acute chronic pancreatitis~* Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications.~Within 3 months prior to screening:~* Have poorly controlled hypertension~* Have history of acute myocardial infarction~* Have history of cerebrovascular accident (stroke)~* Had hospitalization due to congestive heart failure (CHF)~* Have cancer~* Have human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening~* Have hepatitis B and/or positive hepatitis B surface antigen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 12 milligram (mg) LY3502970 (Type: EXPERIMENTAL): Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
- 24 mg LY3502970 (Type: EXPERIMENTAL): Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
- 36 mg-1 LY3502970 (Type: EXPERIMENTAL): Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
- 36 mg-2 LY3502970 (Type: EXPERIMENTAL): Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
- 45 mg-1 LY3502970 (Type: EXPERIMENTAL): Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
- 45 mg-2 LY3502970 (Type: EXPERIMENTAL): Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered orally once daily until 36 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).